Durvalumab (Imfinzi®) is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||29/03/2019|
|Rapid review completed||29/04/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||01/05/2019|
|Pre-submission consultation with Applicant||10/06/2019|
|Submission received from Applicant||30/08/2019|
|Preliminary review sent to Applicant||20/12/2019|
|NCPE assessment re-commenced||30/01/2020|
|Factual accuracy sent to Applicant||16/04/2020|
|NCPE assessment re-commenced||24/04/2020|
|NCPE assessment completed||07/05/2020|
|NCPE assessment outcome||The NCPE recommends that durvalumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.